Comparative analysis of canadian ‘certificate of supplementary protection’ with USA and Australian ‘patent term extension’ and European ‘supplementary protection certificate’

Archna Roy, Mayur Kardile, Manthan Janodia

Research output: Contribution to journalArticle

Abstract

As a result of Comprehensive Economic and Trade Agreement (CETA), for the first time, on 21 September 2017, Canada introduced Certificate of Supplementary Protection (CSP) regime. Before CETA was executed, Canada was the only country of G7 (Group of 7) countries not to legislate Patent Term Extension (PTE). This new regime is an important moment for the Canada’s intellectual property (IP) framework. On one hand, this regime provides an opportunity to innovators of pharmaceutical and veterinary products to recover investments made to obtain marketing authorizations for medicinal products, and on other hand, it impacts the timing of entry of generic products in the Canadian market. This article provides comprehensive information regarding the Canadian CSP and its comparative analysis with United States of America and Australian PTE and European Supplementary Protection Certificate (SPC).

Original languageEnglish
Pages (from-to)167-173
Number of pages7
JournalJournal of Intellectual Property Rights
Volume23
Issue number4-5
Publication statusPublished - 01-07-2018

Fingerprint

patent
certification
Canada
regime
innovator
authorization
intellectual property
pharmaceutical
economics
marketing
market
Group

All Science Journal Classification (ASJC) codes

  • Law

Cite this

@article{6f1d98a5f29d4a9ebb445ca652911660,
title = "Comparative analysis of canadian ‘certificate of supplementary protection’ with USA and Australian ‘patent term extension’ and European ‘supplementary protection certificate’",
abstract = "As a result of Comprehensive Economic and Trade Agreement (CETA), for the first time, on 21 September 2017, Canada introduced Certificate of Supplementary Protection (CSP) regime. Before CETA was executed, Canada was the only country of G7 (Group of 7) countries not to legislate Patent Term Extension (PTE). This new regime is an important moment for the Canada’s intellectual property (IP) framework. On one hand, this regime provides an opportunity to innovators of pharmaceutical and veterinary products to recover investments made to obtain marketing authorizations for medicinal products, and on other hand, it impacts the timing of entry of generic products in the Canadian market. This article provides comprehensive information regarding the Canadian CSP and its comparative analysis with United States of America and Australian PTE and European Supplementary Protection Certificate (SPC).",
author = "Archna Roy and Mayur Kardile and Manthan Janodia",
year = "2018",
month = "7",
day = "1",
language = "English",
volume = "23",
pages = "167--173",
journal = "Journal of Intellectual Property Rights",
issn = "0971-7544",
publisher = "National Institute of Science Communication and Information Resources (NISCAIR)",
number = "4-5",

}

TY - JOUR

T1 - Comparative analysis of canadian ‘certificate of supplementary protection’ with USA and Australian ‘patent term extension’ and European ‘supplementary protection certificate’

AU - Roy, Archna

AU - Kardile, Mayur

AU - Janodia, Manthan

PY - 2018/7/1

Y1 - 2018/7/1

N2 - As a result of Comprehensive Economic and Trade Agreement (CETA), for the first time, on 21 September 2017, Canada introduced Certificate of Supplementary Protection (CSP) regime. Before CETA was executed, Canada was the only country of G7 (Group of 7) countries not to legislate Patent Term Extension (PTE). This new regime is an important moment for the Canada’s intellectual property (IP) framework. On one hand, this regime provides an opportunity to innovators of pharmaceutical and veterinary products to recover investments made to obtain marketing authorizations for medicinal products, and on other hand, it impacts the timing of entry of generic products in the Canadian market. This article provides comprehensive information regarding the Canadian CSP and its comparative analysis with United States of America and Australian PTE and European Supplementary Protection Certificate (SPC).

AB - As a result of Comprehensive Economic and Trade Agreement (CETA), for the first time, on 21 September 2017, Canada introduced Certificate of Supplementary Protection (CSP) regime. Before CETA was executed, Canada was the only country of G7 (Group of 7) countries not to legislate Patent Term Extension (PTE). This new regime is an important moment for the Canada’s intellectual property (IP) framework. On one hand, this regime provides an opportunity to innovators of pharmaceutical and veterinary products to recover investments made to obtain marketing authorizations for medicinal products, and on other hand, it impacts the timing of entry of generic products in the Canadian market. This article provides comprehensive information regarding the Canadian CSP and its comparative analysis with United States of America and Australian PTE and European Supplementary Protection Certificate (SPC).

UR - http://www.scopus.com/inward/record.url?scp=85064526566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064526566&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 167

EP - 173

JO - Journal of Intellectual Property Rights

JF - Journal of Intellectual Property Rights

SN - 0971-7544

IS - 4-5

ER -